1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Relmada Hopes Open-Label Efficacy, Safety Bolster Profile Of Depression Candidate

 
• By Joseph Haas

With a pair of Phase III setbacks due to high placebo response, Relmada reports positive efficacy and safety data from an open-label trial while awaiting data from two ongoing pivotal studies for REL-1017, an NMDA antagonist.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image

Ahead of a pair of pivotal Phase III trial readouts expected in 2024, Relmada Therapeutics, Inc. released data from an open-label Phase III trial of REL-1017 on 20 September which it said showed clinically meaningful and sustained improvements in depression symptoms and associated functional impairment while continuing to support a safety profile that might give the NMDA antagonist an edge in the competitive depression space.

Key Takeaways

 

    •  

    •  

    The drug’s prospects took a hit last October when the pivotal Phase III RELIANCE-III study failed to hit its primary...

    Read the full article – start your free trial today!

    Join thousands of industry professionals who rely on Scrip for daily insights

    • Start your 7-day free trial
    • Explore trusted news, analysis, and insights
    • Access comprehensive global coverage
    • Enjoy instant access – no credit card required
    Start Free Trial

    Already a subscriber?

    More from Clinical Trials

    J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

     
    • By Alaric DeArment

    The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

    ASCO: Pushing The Frontiers Of ADCs

     
    • By Mary Jo Laffler

    Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

    Skyhawk Looks To Soar With Huntington’s Hope

     
    • By Kevin Grogan

    Oral RNA splicing modulator has gone into a Phase II/III trial

    Scholar Rock Shows Muscle-Building PoC In Obesity

     
    • By Jessica Merrill

    The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

    More from R&D

    Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

     
    • By Andrew McConaghie

    The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

    Ireland’s Got Biopharma Talent To Keep Leading The Pack

     
    • By Kevin Grogan

    The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

    Draig Is All Fired Up To Transform Neuropsychiatric Field

     
    • By Kevin Grogan

    Wales-based group launches with $140m series A.